CDLX Form 4: RSU vesting increases holdings before tax-withholding sale
Rhea-AI Filing Summary
Nick Lynton, Chief Legal & Privacy Officer of Cardlytics, Inc. (CDLX), reported multiple vesting and a sale related to restricted stock units. On 10/01/2025 the reporting person had 10,630, 581 and 1,578 RSUs treated as acquired (each converts into one share) and those awards increased their reported beneficial ownership to 122,425 shares before a sale. On 10/02/2025 the reporting person sold 6,098 shares at a weighted average price of $2.271 (individual sale prices ranged $2.21–$2.36) and the filing shows 116,327 shares owned after the sale. The filing states the sale was made solely to satisfy tax withholding from RSU vesting and discloses original grant sizes and vesting schedules for each RSU award.
Positive
- 10,630 RSUs vested (converted to shares), reflecting awarded equity retention
- Filing discloses detailed vesting schedules for RSU awards, clarifying future equity vesting timing
Negative
- Sale of 6,098 shares reduced beneficial ownership to 116,327
- Shares sold at a weighted average price of $2.271, within a range of $2.21–$2.36
Insights
Insider reported RSU vesting and a tax-related sale, reducing holdings to 116,327 shares.
The Form 4 documents conversion of multiple RSU awards on 10/01/2025, increasing pre-sale beneficial ownership to 122,425 shares. The filing then records a sale of 6,098 shares on 10/02/2025 at a weighted average price of $2.271.
This transaction is disclosed as a tax-withholding sale tied to RSU vesting; such sales are routine for employees and do not indicate opportunistic selling beyond withholding needs. The form also lists original award sizes and vesting schedules, which clarify ongoing equity-based compensation and retention mechanics.
FAQ
What did Cardlytics insider Nick Lynton report on Form 4 (CDLX)?
Why were 6,098 shares sold by the reporting person?
At what price were the shares sold?
How many RSUs vested and what is their conversion?
What are the vesting schedules disclosed?